Treatment of Melanoma/Renal Cell Carcinoma

Total Page：16

File Type：pdf, Size：1020Kb

Request title: Treatment of Melanoma/Renal Cell Carcinoma Reference Number: F4066 Date of Response: 15/07/2021 Further to your Freedom of Information Act request, please find the Trust’s response, in blue bold text below: Request and Royal Devon and Exeter NHS Foundation Trust Response I am researching the incidence and treatment of melanoma and renal cell carcinoma. Could you please answer the following three questions; Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma: Avelumab + Axitinib * ≤5 Axinitib * ≤5 Cabozantinib * ≤5 Everolimus 0 Lenvantinib + Everolimus 0 Nivolumab 9 Nivolumab + Ipilimumab * ≤5 Pazopanib 6 Pembrolizumab + Axitinib 0 Sunitinib 11 Temsirolimus 0 Tivozanib 0 Other 0 * ≤5. In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles. This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG’s providers and Trusts may allow identification of patients and should not be published. Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage): Cobimetinib Dabrafenib * ≤5 Dabrafenib + Trametinib 11 Encorafenib + Binimetinib * ≤5 Ipilimumab * ≤5 Ipilimumab + Nivolumab * ≤5 Nivolumab 18 Pembrolizumab 23 Trametinib 0 Vemurafenib 0 Vemurafenib + Cobimetinib 0 Other active systemic anti-cancer therapy * ≤5 Palliative care only 0 3. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY: Cobimetinib 0 Dabrafenib * ≤5 Dabrafenib + Trametinib 7 Encorafenib + Binimetinib * ≤5 Ipilimumab * ≤5 Ipilimumab + Nivolumab * ≤5 Nivolumab 16 Pembrolizumab 16 Trametinib 0 Vemurafenib 0 Vemurafenib + Cobimetinib 0 Other active systemic anti-cancer therapy * ≤5 Palliative care only * ≤5 .

Copy Link

Recommended publications

Oncofocus® Precision Oncology
Medical Laboratory Accredited to ISO15189:2012 Oncofocus® Precision Oncology ONCOFOCUS® TEST REPORT Oncologica UK Ltd Suite 15-16, The Science Village Chesterford Research Park Cambridge, CB10 1XL, UK Tel: +44(0)1223 785327 Email: [email protected] Lead Clinical Scientist: - Pre-Reg Clinical Scientist: - Date: 1 of 30 ONC19 - Surname - Requester - Forename - Contact details - DOB - Date requested - Gender - Histology # - Tumour % - Primary site Breast Tumour % - Tumour subtype - (macrodissected) Tissue Type - Comment: The DNA and RNA extracted from this sample were of optimal quality. The Oncofocus assay on which the sample was run met all assay specific quality metrics. Oncofocus currently targets 505 genes covering oncogenes, fusion genes, genes susceptible to copy number variation and tumour suppressors. Actionable genetic variants detected by Oncofocus are currently linked to 687 anti-cancer targeted therapies/therapy combinations. The following actionable variants were detected: Within the 'Current Clinical Trials Information' section of this report, starting on page 8, the NCT numbers are hyperlinks to the clinicaltrials.gov webpages which should be accessed to gain further trial specific information Sample Cancer Type: Breast Cancer Clinically Significant Biomarkers Indicated Contraindicated Relevant Therapies Relevant Therapies Genomic Alteration Alt allele freq (In this cancer type) (In other cancer type) Clinical Trials ERBB2 p.(G727A) c.2180G>C 39% Clinical trials and/or off-label ado-trastuzumab emtansine 19 BRAF p.(V600E) c.1799T>A 5% Clinical trials and/or off-label dabrafenib 13 vemurafenib PIK3CA p.(G1049R) c.3145G>C 58% Clinical trials and/or off-label Clinical trials and/or off-label 15 Sources included in relevant therapies: EMA1, FDA2, ESMO, NCCN Hotspot variants with >10% alternate allele reads are classified as ‘detected’ with an assay sensitivity and positive predictive value(PPV) of 99%.
[Show full text]
Product Monograph Including Patient Medication Information
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr ® COTELLIC cobimetinib tablets 20 mg cobimetinib (as cobimetinib fumarate) Protein Kinase Inhibitor Date of Revision: Hoffmann-La Roche Limited January 5, 2018 7070 Mississauga Road Mississauga, Ontario, Canada L5N 5M8 www.rochecanada.com Submission Control No: 209926 COTELLIC®, ZELBORAF® are registered trade-marks of F. Hoffmann-La Roche AG, used under license ©Copyright 2016-2017, Hoffmann-La Roche Limited Page 1 of 38 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ..................................................................................................11 DRUG INTERACTIONS ..................................................................................................15 DOSAGE AND ADMINISTRATION ..............................................................................17 OVERDOSAGE ................................................................................................................20 ACTION AND CLINICAL PHARMACOLOGY ............................................................20
[Show full text]
Quantification of Cobimetinib, Cabozantinib, Dabrafenib, Niraparib
University of Groningen Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC-MS/MS Krens, Stefanie D; van der Meulen, Eric; Jansman, Frank G A; Burger, David M; van Erp, Nielka P Published in: Biomedical chromatography DOI: 10.1002/bmc.4758 IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2020 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Krens, S. D., van der Meulen, E., Jansman, F. G. A., Burger, D. M., & van Erp, N. P. (2020). Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC-MS/MS. Biomedical chromatography, 34(3), [4758]. https://doi.org/10.1002/bmc.4758 Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne- amendment. Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
[Show full text]
Successful Chemotherapy Is Possible for Seemingly Inoperable Anaplastic Thyroid Cancer
® Clinical Thyroidology for the Public VOLUME 12 | ISSUE 12 | DECEMBER 2019 THYROID CANCER Successful chemotherapy is possible for seemingly inoperable anaplastic thyroid cancer BACKGROUND form of standard chemotherapy and 2 received another While the vast majority of thyroid cancers are slow tyrosine kinase inhibitor called pembrolizumab. Of the 6 growing and have an excellent prognosis, anaplastic patients that had surgery after this treatment, 4 patients thyroid cancer, which makes up <1% of all thyroid cancer, had the entire primary cancer removed and the other 2 is one of the most aggressive of all cancers, with a survival patients only had microscopic pieces of cancer left after averaging ~6 months after diagnosis. Surgery, radiation the surgery. After the surgery, 5 of 6 patients received and single drug chemotherapy is all ineffective in most standard chemotherapy and radiation to the surgical area. cases. The aim of this study is to study if combination Of the 6 patients, 4 patients had no evidence of cancer at chemotherapy will make previously inoperable anaplastic the last check, some over 2 years after surgery. The 2 other thyroid cancers safe to remove with surgery. patients did pass away from anaplastic cancer; however, there was no re-growth of cancer in the area where surgery THE FULL ARTICLE TITLE occurred. Wang JR et al 2019 Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAFV600E- WHAT ARE THE IMPLICATIONS mutated anaplastic thyroid carcinoma. Thyroid 29:1036– OF THIS STUDY? 1043. PMID: 31319771. In selected patients with anaplastic thyroid cancer with the BRAF V600E mutation, treatment with dabrafenib SUMMARY OF THE STUDY and trametinib may increase the chance of having a In this study from the MD Anderson Cancer Center successful surgery of the primary tumor.
[Show full text]
New Oncology Reimbursements in Belgium
33 New oncology reimbursements in Belgium P. Specenier, MD, PhD OVERVIEW OF BELGIAN REIMBURSEMENT NEWS (BELG J MED ONCOL 2018;12(1):33-34) TEMOZOLOMIDE® (TEMODAR/TEMODAL) was 7.4 months (95% confidence interval [CI] 5.6-9.1) with Some companies have transferred temozolomide from chap- cabozantinib versus 3.8 months (95% CI 3.7-5.4) with ever- ter IV to chapter I. These can now be prescribed without re- olimus with a hazard ratio (HR) of 0.58 (95% CI 0.45-0.74; strictions. In the near future, other temozolomide brands are p<0.0001). Similar data were observed in the intent-to-treat also expected to be transferred. population. A planned interim analysis of overall survival (OS) was conducted at the time of the PFS analysis and did LOMUSTINE (CCNU) not reach the interim boundary for statistical significance The reimbursement criteria for lomustine have been modi- (HR=0.68 [0.51, 0.90], p=0.006). However, in a subsequent fied and are entirely concordant with the recently modified unplanned interim analysis of OS, a statistically significant criteria for procarbazine, except for the indication Hodgkin’s improvement was demonstrated (median 21.4 months ver- disease, which only applies for procarbazine. sus 16.5 months; HR=0.66; 95% CI 0.53-0.83; p=0.0003). The overall response rate (ORR) was 17% (95% CI 13-22) for CABOMETYX® (CABOZANTINIB) cabozantinib and 3% (95% CI 2-6) for everolimus (p<0.0001). Cabometyx® (cabozantinib) can be reimbursed for patients with advanced renal cell carcinoma (RCC) after at least one COTELLIC® (COBIMETINIB) prior anti-VEGF directed agent.
[Show full text]
Combined BRAF and MEK Inhibition with Vemurafenib and Cobimetinib for Patients with Advanced Melanoma
Review Melanoma Combined BRAF and MEK Inhibition with Vemurafenib and Cobimetinib for Patients with Advanced Melanoma Antonio M Grimaldi, Ester Simeone, Lucia Festino, Vito Vanella and Paolo A Ascierto Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione “G. Pascale”, Napoli, Italy cquired resistance is the most common cause of BRAF inhibitor monotherapy treatment failure, with the majority of patients experiencing disease progression with a median progression-free survival of 6-8 months. As such, there has been considerable A focus on combined therapy with dual BRAF and MEK inhibition as a means to improve outcomes compared with monotherapy. In the COMBI-d and COMBI-v trials, combined dabrafenib and trametinib was associated with significant improvements in outcomes compared with dabrafenib or vemurafenib monotherapy, in patients with BRAF-mutant metastatic melanoma. The combination of vemurafenib and cobimetinib has also been investigated. In the phase III CoBRIM study in patients with unresectable stage III-IV BRAF-mutant melanoma, treatment with vemurafenib and cobimetinib resulted in significantly longer progression-free survival and overall survival (OS) compared with vemurafenib alone. One-year OS was 74.5% in the vemurafenib and cobimetinib group and 63.8% in the vemurafenib group, while 2-year OS rates were 48.3% and 38.0%, respectively. The combination was also well tolerated, with a lower incidence of cutaneous squamous-cell carcinoma and keratoacanthoma compared with monotherapy. Dual inhibition of both MEK and BRAF appears to provide a more potent and durable anti-tumour effect than BRAF monotherapy, helping to prevent acquired resistance as well as decreasing adverse events related to BRAF inhibitor-induced activation of the MAPK-pathway.
[Show full text]
Preferential Response of Basal-Like Head and Neck Squamous Cell Carcinoma Cell Lines to EGFR-Targeted Therapy Depending on EREG-Driven Oncogenic Addiction
Article Preferential Response of Basal-Like Head and Neck Squamous Cell Carcinoma Cell Lines to EGFR-Targeted Therapy Depending on EREG-Driven Oncogenic Addiction Sylvie Job 1, Aurélien de Reyniès 1, Betty Heller 2, Amélie Weiss 2, Eric Guérin 3,4, Christine Macabre 4,5, Sonia Ledrappier 4,5, Cyril Bour 4,5, Christine Wasylyk 2, Nelly Etienne-Selloum 5,6, Laurent Brino 2, Christian Gaiddon 4, Bohdan Wasylyk 2,† and Alain C. Jung 4,5,†,* 1 Programme Cartes d’Identité des Tumeurs (CIT), Ligue Nationale Contre le Cancer, 75013 Paris, France; [email protected] (S.J.); [email protected] (A.d.R.) 2 Institut de Génétique et de Biologie Moléculaire et Cellulaire IGBMC, UMR 7104 CNRS-UdS, U.1258 INSERM, 1 rue Laurent Fries, BP 10142, 67404 Illkirch cedex, France.; [email protected] (B.H.); [email protected] (A.W.); [email protected] (C.W.); [email protected] (L.B.); [email protected] (B.W.) 3 Laboratoire de Biochimie et Biologie Moléculaire, Hôpitaux Universitaires de Strasbourg, 67098 Strasbourg, France; [email protected] 4 Université de Strasbourg, Inserm, UMR_S1113, 67200 Strasbourg, France; [email protected] (C.M.); [email protected] (S.L.); [email protected] (C.B.); [email protected] (C.G.) 5 Centre de Lutte Contre le Cancer Paul Strauss, 67000 Strasbourg, France; [email protected] 6 UMR 7021 CNRS/Unistra, Laboratoire de Bioimagerie et Pathologies (LBP), Faculté de Pharmacie, 67401 Illkirch, France * Correspondence: [email protected]; Tel.: +33-0388275367 † These authors contributed equally to this work.
[Show full text]
Original Research Paper In-Silico FDA-Approved Drug Repurposing to Find
Original Research Paper In-silico FDA-approved drug repurposing to find the possible treatment of Coronavirus Disease-19 (COVID-19) Kumar Sharp1, Dr. Shubhangi Dange2* 12nd MBBS undergraduate student, Government Medical College and Hospital, Jalgaon 2Associate Professor, Dept. of Microbiology, Government Medical College and Hospital, Jalgaon *Corresponding author: - Dr. Shubhangi Dange, Associate Professor, Department of Microbiology, Government Medical College and Hospital, Jalgaon Email: [email protected] Abstract Identification of potential drug-target interaction for approved drugs serves as the basis of repurposing drugs. Studies have shown polypharmacology as common phenomenon. In-silico approaches help in screening large compound libraries at once which could take years in a laboratory. We screened a library of 1050 FDA-approved drugs against spike glycoprotein of SARS-CoV2 in-silico. Anti-cancer drugs have shown good binding affinity which is much better than hydroxychloroquine and arbidol. We have also introduced a hypothesis named “Bump” hypothesis which and be developed further in field of computational biology. Keywords: spike glycoprotein; FDA; drug repurposing; anti-cancer; hydroxychloroquine Introduction Identification of potential drug-target interaction for approved drugs serves as the basis of repurposing drugs. Studies have shown polypharmacology as common phenomenon [1][2]. Since the three-dimensional structures of proteins of SARS-CoV2 have been mapped it opens opportunity for in-silico approaches of either novel drug discovery or drug repurposing. In the absence of an exact cure or vaccine, coronavirus disease-19 has taken a huge toll of humanity. Our study of target specific drug docking and novel hypothesis contributes in this fight. In-silico approaches help in screening large compound libraries at once which could take years in a laboratory.
[Show full text]
Tafinlar, INN-Dabrafenib
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Tafinlar 50 mg hard capsules Tafinlar 75 mg hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Tafinlar 50 mg hard capsules Each hard capsule contains dabrafenib mesilate equivalent to 50 mg of dabrafenib. Tafinlar 75 mg hard capsules Each hard capsule contains dabrafenib mesilate equivalent to 75 mg of dabrafenib. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Hard capsule (capsule). Tafinlar 50 mg hard capsules Opaque dark red capsules, approximately 18 mm long, with capsule shell imprinted with “GS TEW” and “50 mg”. Tafinlar 75 mg hard capsules Opaque dark pink capsules, approximately 19 mm long, with capsule shell imprinted with “GS LHF” and “75 mg”. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Melanoma Dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 and 5.1). Adjuvant treatment of melanoma Dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection. Non-small cell lung cancer (NSCLC) Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation. 2 4.2 Posology and method of administration Treatment with dabrafenib should be initiated and supervised by a qualified physician experienced in the use of anticancer medicinal products. Before taking dabrafenib, patients must have confirmation of tumour BRAF V600 mutation using a validated test.
[Show full text]
Cotellic, INN-Cobimetinib
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Cotellic 20 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains cobimetinib hemifumarate equivalent to 20 mg cobimetinib. Excipient with known effect Each film-coated tablet contains 36 mg lactose monohydrate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. White, round film-coated tablets of approximately 6.6 mm diameter, with “COB” debossed on one side. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 and 5.1). 4.2 Posology and method of administration Treatment with Cotellic in combination with vemurafenib should only be initiated and supervised by a qualified physician experienced in the use of anticancer medicinal products. Before starting this treatment, patients must have BRAF V600 mutation-positive melanoma tumour status confirmed by a validated test (see sections 4.4 and 5.1). Posology The recommended dose of Cotellic is 60 mg (3 tablets of 20 mg) once daily. Cotellic is taken on a 28 day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken once daily for 21 consecutive days (Days 1 to 21-treatment period); followed by a 7-day break (Days 22 to 28-treatment break). Each subsequent Cotellic treatment cycle should start after the 7-day treatment break has elapsed. For information on the posology of vemurafenib, please refer to its SmPC.
[Show full text]
Oncology Drug Shortage Update
] ] [ News ] Analysis ] Commentary ] Controversy ] June 25, 2013 Vol. 35 No. 12 oncology-times.com ONCOLOGY e 5 Y ars 3 of g P in u t b a l r i s b h e i l n e g IMES C 35 TThe Independent Hem/Onc News Source Oncology Drug Shortage Update BY HEATHER LINDSEY new survey documents that cancer drug shortages have occurred A frequently, led to treatment delays, increased the risks of errors and adverse outcomes, complicated research, and increased the costs of medications� The survey, by the Hematology-Oncology Pharmacy Association, is the first to focus specifically on oncology� Page 14 • Advanced NSCLC: 60 Gy Standard • Seminoma: Opting Out of Adjuvant Therapy Safe LUNG CANCER: • Immunotherapy ‘Poised to Change Treatment Paradigm’ Leukemia Researcher Lukas Meeting Spotlights • DLBCL: CT Surveillance Adds Little Value Wartman Describes 10-Year Progress in Molecularly • CLL: Enthusiasm for Idelalisb Personal Battle Against Guided Therapy p.10 • Fitness & Cancer Prognosis pp.18, 25, 28, 33, 36, 37 Adult ALL p.20 [ALSO] SHOP TALK �� 3 EDITH PEREZ: How I Treat Patients with Advanced HER2-Positive Breast Cancer � � � � � � � � � � �5 Exercise, Estrogen, & Breast Cancer Risk: New Data �� 11 JOE SIMONE: Changing Views of Leaders and Leadership � � � � � � � � � � � � � � � � � � � � � � � � � � � � �16 Science Symposium for ACS’s 100th Anniversary ��
[Show full text]
Cobimetinib/Vemurafenib Combination Therapy for Melanoma: a Nursing Tool from the Melanoma Nursing Initiative (MNI)
Cobimetinib/Vemurafenib Combination Therapy for Melanoma: A Nursing Tool From The Melanoma Nursing Initiative (MNI) Cobimetinib (Cotellic®)/vemurafenib (Zelboraf®) combination therapy is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations. Cobimetinib is a MEK1 and MEK2 inhibitor, and vemurafenib is an inhibitor of some mutated forms of BRAF kinase, including BRAF V600E. About half of patients with melanoma have a mutated form of the BRAF protein in their tumors. Combination MEK/ BRAF inhibitor therapy is associated with superior tumor response and improved patient survival compared with single-agent BRAF inhibitor therapy. Using the combination also decreases the high rates of secondary cutaneous malignancies associated with single-agent BRAF inhibitory therapy. This document is part of an overall nursing toolkit intended to assist nurses in optimizing care of melanoma patients receiving newer anti-melanoma therapies. © 2017 The Melanoma Nursing Initiative. All rights reserved www.themelanomanurse.org Inspired By Patients . Empowered By Knowledge . Impacting Melanoma DRUG-DOSING/ADMINISTRATION • For advanced melanoma, both cobimetinib and vemurafenib are orally administered drugs. Cobimetinib is administered as 60 mg (three 20-mg tablets) once daily for 3 weeks, followed by a 1-week break, and vemurafenib as 960 mg (four 240-mg tablets) twice daily, for a total daily dosage of 1920 mg, each according to the regimens outlined below. The cobimetinib dose can be taken at the same time as one of the vemurafenib doses. The schedule repeats until disease progression or unacceptable toxicity occurs. • If the patient misses a dose of cobimetinib or vemurafenib, adjust as follows: » Cobimetinib: If ≤4 hours from scheduled dosing time, take the dose.
[Show full text]